The London is taking part in Amgen's Expanded Access program, which will run until March 2010. Patients need to have received a prior therapy and will need to live relatively near the London since there are weekly visits during the initial phase of the study.
We are talking to a couple of biotech companies who are looking to run Phase 3 trials of new ITP medicines. Once we know more we will post an update here.